Thyroid stimulating hormone test paper as well as preparation method and application thereof

Through the development of thyroid stimulating hormone detection test strips, the problem of long TSH detection time in the existing technology was solved by using peripheral blood samples and fluorescent microsphere immunochromatography technology, and the problem of long TSH detection time was achieved, which achieved rapid and accurate detection, satisfying the patient's TSH detection need.

CN118937703APending Publication Date: 2024-11-12HUNAN PROVINCIAL TUMOR HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411073266.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the prior art, thyroid hormone (TSH) detection requires intravenous blood collection and the result time is long, which cannot meet the patient's rapid testing needs.

Method used

Develop a test paper for thyroid stimulating hormone detection using peripheral blood samples for fluorescent microsphere immunochromatography technology. Through the combined structure of blood filter pad, antibody pad, solid phase carrier and water absorption paper, combined with fluorescent microsphere labeled thyroid stimulating hormone antibodies , realize fast and accurate TSH detection.

Benefits of technology

No need for intravenous blood collection, accurate TSH test results can be obtained in just 15 to 20 minutes, which improves the detection efficiency and allows patients to conduct simple home monitoring.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937703A_ABST
    Figure CN118937703A_ABST
Patent Text Reader

Abstract

The invention discloses thyroid stimulating hormone detection test paper as well as a preparation method and application thereof. The thyroid stimulating hormone detection test paper comprises a blood filtering pad 1, an antibody pad 2, a solid-phase carrier 3, absorbent paper 4 and a bottom plate 5, the blood filtering pad 1, the antibody pad 2, the solid-phase carrier 3 and the absorbent paper 4 are arranged on the bottom plate 5, two ends of the antibody pad 2 are respectively connected with the blood filtering pad 1 and the solid-phase carrier 3, and one end, far away from the antibody pad 2, of the solid-phase carrier 3 is connected with the absorbent paper 4. According to the thyroid stimulating hormone test paper, vein blood sampling is not needed, an accurate quantitative result can be obtained based on a peripheral blood sample, the detection time is short, and a detection result can be obtained in 15-20 minutes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medical detection, and specifically relates to a thyroid stimulating hormone detection test strip and a preparation method and application thereof. Background Art

[0002] At present, the number of patients with thyroid diseases in endocrine clinics may be second only to the number of patients with diabetes. Patients with hypothyroidism often use levothyroxine (L-T4) as a monotherapy for life, and need to continuously monitor the level of thyroid stimulating hormone (TSH). Pregnant patients with hypothyroidism only need to monitor TSH levels. The dosage of antithyroid drugs for patients with hyperthyroidism should be determined according to the levels of TSH, tetraiodothyronine (T4) and triiodothyronine (T3). Pregnant patients with hyperthyroidism need to monitor FT4 and serum total thyroxine (TT4). The dosage of L-T4 for patients with thyroid cancer after surgery should be determined according to the levels of TSH and FT4. If the serum TSH of patients who do not undergo surgery is found to be >2.0 mU / L in early pregnancy, L-T4 treatment can be recommended to control the serum TSH at 0.3~2.0 mU / L. TSH testing is a preliminary screening test for thyroid function. A slight change in the concentration of free thyroxine will result in a significant change in the TSH concentration in the opposite direction. The assessment of TSH concentration is particularly suitable for early detection or exclusion of functional disorders in the hypothalamus-pituitary-thyroid central regulatory circuit; it has important clinical significance in the diagnosis of diseases such as primary hyperthyroidism, thyroid cancer, chronic lymphocytic thyroiditis, thyroid nodules or nodular goiter.

[0003] However, current clinical monitoring of TSH still requires patients to go to the hospital to register and have blood drawn for examination. Venous blood needs to be drawn for TSH testing based on the chemiluminescence method, and the test results require a long wait, which cannot meet the current patient needs for TSH testing. Summary of the invention

[0004] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention proposes a thyroid stimulating hormone test strip, which does not require venous blood sampling, can obtain accurate quantitative results based on peripheral blood samples, and the time required for detection is short, and the test results can be obtained in 15 to 20 minutes.

[0005] The invention also provides a method for preparing the thyroid stimulating hormone test strip.

[0006] The present invention also provides an application.

[0007] The present invention also provides a kit.

[0008] According to a first aspect of the present invention, a thyroid stimulating hormone test strip is provided, the thyroid stimulating hormone test strip comprising: a blood filter pad 1, an antibody pad 2, a solid phase carrier 3, a water-absorbing paper 4 and a bottom plate 5; The blood filter pad 1, antibody pad 2, solid phase carrier 3 and absorbent paper 4 are arranged on the bottom plate 5. The two ends of the antibody pad 2 are connected to the blood filter pad 1 and the solid phase carrier 3 respectively. One end of the solid phase carrier 3 away from the antibody pad 2 is connected to the absorbent paper 4; The solid phase carrier 3 is provided with a detection line 31 and a quality control line 32 spaced apart from each other, the detection line 31 is located at one end close to the antibody pad 2, and the quality control line 32 is located at one end close to the absorbent paper 4; The surface of the antibody pad 2 is coated with a first thyroid stimulating hormone antibody labeled with fluorescent microspheres; The detection line 31 is fixed with a second thyroid stimulating hormone antibody; A quality control antibody is fixed on the quality control line 32 , and the quality control antibody can specifically bind to the first thyroid stimulating hormone antibody.

[0009] In some embodiments of the present invention, the blood filter pad 1 comprises a glass fiber membrane.

[0010] In some preferred embodiments of the present invention, the gram weight of the glass fiber membrane is 100-110 g / m 2 .

[0011] In some preferred embodiments of the present invention, the glass fiber membrane has a thickness of 0.41-0.51 mm.

[0012] In some preferred embodiments of the present invention, the climbing speed of the glass fiber membrane is 30-50 mm / 60 s.

[0013] In some preferred embodiments of the present invention, the water storage capacity of the glass fiber membrane is 550-700 g / m 2 .

[0014] In some preferred embodiments of the present invention, the glass fiber membrane is prepared using fine glass fibers with a diameter of 0.6-3 nm.

[0015] In some embodiments of the present invention, the antibody pad 2 comprises a polyester fiber membrane.

[0016] In some preferred embodiments of the present invention, the weight of the polyester fiber film is 85-110 g / m 2 .

[0017] In some preferred embodiments of the present invention, the thickness of the polyester fiber film is 0.37-0.53 mm.

[0018] In some preferred embodiments of the present invention, the climbing speed of the polyester fiber membrane is 10-20 s / 4 cm.

[0019] In some preferred embodiments of the present invention, the water storage capacity of the polyester fiber membrane is 480-680 g / m 2 .

[0020] In some embodiments of the present invention, the solid phase carrier 3 comprises a nitrocellulose membrane.

[0021] In some preferred embodiments of the present invention, the thickness of the nitrocellulose membrane is 180-220 μm.

[0022] In some preferred embodiments of the present invention, the creeping speed of the nitrocellulose membrane is 150-225 s / 4cm.

[0023] In some preferred embodiments of the present invention, the protein binding capacity of the nitrocellulose membrane is greater than 45 μg / cm 2 (BSA).

[0024] In some embodiments of the present invention, the gram weight of the absorbent paper 4 is 350-420 g / m 2 .

[0025] In some embodiments of the present invention, the absorbent paper 4 has a thickness of 0.87-1.13 mm.

[0026] In some embodiments of the present invention, the creeping speed of the absorbent paper 4 is 40-80 s / 4 cm.

[0027] In some embodiments of the present invention, the water storage capacity of the absorbent paper 4 is 600-900 g / m 2 .

[0028] In some embodiments of the present invention, the bottom plate 5 comprises PVC.

[0029] In some embodiments of the present invention, the mass ratio of the fluorescent microspheres to the first thyroid stimulating hormone antibody is (5-15):1.

[0030] In some preferred embodiments of the present invention, the mass ratio of the fluorescent microspheres to the first thyroid stimulating hormone antibody is (8-12):1.

[0031] In some more preferred embodiments of the present invention, the mass ratio of the fluorescent microspheres to the first thyroid stimulating hormone antibody is 10:1.

[0032] In some embodiments of the present invention, the fluorescent microspheres include a high molecular polymer containing a rare earth element.

[0033] In some preferred embodiments of the present invention, the fluorescent microspheres include polystyrene polymers containing rare earth elements.

[0034] In some preferred embodiments of the present invention, the diameter of the fluorescent microspheres is 200-400 nm.

[0035] In some preferred embodiments of the present invention, the surface of the fluorescent microspheres is modified with carboxyl groups.

[0036] In some embodiments of the invention, the first thyroid stimulating hormone antibody comprises an anti-human thyroid stimulating hormone antibody.

[0037] In some preferred embodiments of the present invention, the first thyroid stimulating hormone antibody is a monoclonal antibody derived from mice.

[0038] In some embodiments of the invention, the second thyroid stimulating hormone antibody comprises an anti-human thyroid stimulating hormone antibody.

[0039] In some preferred embodiments of the present invention, the second thyroid stimulating hormone antibody is a monoclonal antibody derived from mice.

[0040] In some embodiments of the present invention, the quality control antibody comprises goat anti-mouse IgG.

[0041] According to a second aspect of the present invention, a method for preparing a thyroid stimulating hormone test strip as described in the first aspect of the present invention is provided, and the preparation method comprises the following steps: S1: immobilizing the second thyroid stimulating hormone antibody on the solid phase carrier 3 to form a detection line 31, and immobilizing the quality control antibody on the solid phase carrier 3 to form a quality control line 32 spaced apart from the detection line 31; S2: coating the first thyroid stimulating hormone antibody labeled with fluorescent microspheres on the surface of antibody pad 2; S3: Place the blood filter pad 1, the antibody pad 2 coated with the first thyroid stimulating hormone antibody labeled with fluorescent microspheres as described in step S2, the solid phase carrier 3 fixed with the detection line 31 and the quality control line 32 as described in step S1, and the absorbent paper 4 on the bottom plate 5 to obtain a thyroid stimulating hormone test strip.

[0042] In some embodiments of the present invention, the fixing in step S1 includes first scratching the membrane with a membrane scratcher, drying naturally, and then transferring the antibody membrane to 37° C. for drying for 10 to 14 hours.

[0043] In some embodiments of the present invention, the first thyroid stimulating hormone antibody labeled with fluorescent microspheres in step S2 is prepared by the following preparation method: A1: Mix the fluorescent microspheres, 1-ethyl-(3-dimethylaminopropyl)carbodiimide solution and N-hydroxysuccinimide solution to obtain activated fluorescent microspheres; A2: mixing the first thyroid stimulating hormone antibody with the activated fluorescent microspheres obtained in step A1 to obtain the first thyroid stimulating hormone antibody coupled to the fluorescent microspheres; A3: Add the microsphere blocking solution to the first thyroid stimulating hormone antibody coupled with the fluorescent microspheres obtained in step A2 and mix well to react, thereby obtaining the first thyroid stimulating hormone antibody labeled with the fluorescent microspheres.

[0044] In some preferred embodiments of the present invention, the fluorescent microspheres in step A1 are further washed before the reaction.

[0045] In some more preferred embodiments of the present invention, the washing comprises: resuspending the fluorescent microspheres in 50 mmol / L 2-(N-morpholine)ethanesulfonic acid (MES) buffer at pH 5.2, mixing thoroughly, and centrifuging, and repeating the steps of resuspending, mixing, and centrifuging twice.

[0046] In some preferred embodiments of the present invention, the reaction temperature in step A1 is 20-30°C.

[0047] In some more preferred embodiments of the present invention, the reaction temperature in step A1 is 25°C.

[0048] In some preferred embodiments of the present invention, the reaction time in step A1 is 20 to 40 min.

[0049] In some more preferred embodiments of the present invention, the reaction time in step A1 is 30 min.

[0050] In some preferred embodiments of the present invention, the reaction in step A1 is carried out under shaking at 600-800 rpm in the dark.

[0051] In some more preferred embodiments of the present invention, the reaction in step A1 is carried out under shaking at 700 rpm in the dark.

[0052] In some preferred embodiments of the present invention, the concentration of the 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) solution in step A1 is 5 mg / mL.

[0053] In some preferred embodiments of the present invention, the concentration of the N-hydroxysuccinimide (NHS) solution in step A1 is 5 mg / mL.

[0054] In some more preferred embodiments of the present invention, the mixing volume ratio of the EDC solution and the NHS solution in step A1 is 7:66.

[0055] In some preferred embodiments of the present invention, the mass ratio of the fluorescent microspheres in step A1 to the first thyroid stimulating hormone antibody in step A2 is (15-5):1.

[0056] In some preferred embodiments of the present invention, the buffer system of the reaction in step A2 is 10 mmol / L MES buffer (pH 6.2).

[0057] In some preferred embodiments of the present invention, the reaction temperature in step A2 is 20-30°C.

[0058] In some more preferred embodiments of the present invention, the reaction temperature in step A2 is 25°C.

[0059] In some preferred embodiments of the present invention, the reaction time in step A2 is 1 to 3 h.

[0060] In some more preferred embodiments of the present invention, the reaction time in step A2 is 2 h.

[0061] In some preferred embodiments of the present invention, the reaction in step A2 is carried out under shaking at 60-80 rpm in the dark.

[0062] In some more preferred embodiments of the present invention, the reaction in step A2 is carried out under shaking at 70 rpm in the dark.

[0063] In some preferred embodiments of the present invention, the reaction temperature in step A3 is 20-30°C.

[0064] In some more preferred embodiments of the present invention, the reaction temperature in step A3 is 25°C.

[0065] In some preferred embodiments of the present invention, the reaction time in step A3 is 1 to 3 h.

[0066] In some more preferred embodiments of the present invention, the reaction time in step A3 is 1.5 h.

[0067] In some preferred embodiments of the present invention, the reaction in step A3 is carried out under shaking at 60-80 rpm in the dark.

[0068] In some more preferred embodiments of the present invention, the reaction in step A3 is carried out under shaking at 70 rpm in the dark.

[0069] In some preferred embodiments of the present invention, the microsphere blocking solution in step A3 is a 50 mmol / L borate buffer containing the following components: 0.1 v / v% Tween-20, 1 w / v% BSA and 0.24 v / v% ethanolamine.

[0070] In some embodiments of the present invention, the coating in step S2 includes: covering the first thyroid stimulating hormone antibody labeled with fluorescent microspheres on the surface of the antibody pad 2 and drying it, and then drying it at 30-40° C. for 1-3 h.

[0071] In some preferred embodiments of the present invention, the coating in step S2 includes: covering the first thyroid stimulating hormone antibody labeled with fluorescent microspheres on the surface of the antibody pad 2 and drying it, and then drying it at 37° C. for 2 h.

[0072] In some embodiments of the present invention, step S3 further comprises cutting into strips.

[0073] In some preferred embodiments of the present invention, the width of the cut strips is 3-5 mm.

[0074] In some more preferred embodiments of the present invention, the width of the cut strips is 3.8 mm.

[0075] According to the third aspect of the present invention, a use of the thyroid stimulating hormone test strip as described in the first aspect of the present invention in a product for rapid detection of thyroid stimulating hormone is proposed.

[0076] According to a fourth aspect of the present invention, a kit is provided, wherein the kit comprises the thyroid stimulating hormone test strip as described in the first aspect of the present invention.

[0077] In some embodiments of the present invention, the kit further comprises a sampling needle and a sample diluent.

[0078] In some preferred embodiments of the present invention, the sample diluent comprises 10 mM PBS buffer (pH 7.0) containing 1 w / v% bovine serum albumin, 1 w / v% casein, 0.1 w / v% sucrose and 0.4 w / v% Tween-20.

[0079] In some embodiments of the present invention, the kit is used for detecting thyroid stimulating hormone in clinical test samples.

[0080] In some preferred embodiments of the present invention, the sample to be tested includes peripheral blood.

[0081] In some more preferred embodiments of the present invention, the peripheral blood is a whole blood sample.

[0082] In some more preferred embodiments of the present invention, the volume of the sample to be tested is 50-80 μL.

[0083] In some more preferred embodiments of the present invention, the volume of the sample to be tested is 60 μL.

[0084] In some preferred embodiments of the present invention, the detection time required is 15 to 20 min.

[0085] In some embodiments of the present invention, the detection limit of the kit when detecting TSH is 0.10~100.00 μIU / mL.

[0086] The present invention has at least the following beneficial effects: 1) The thyroid stimulating hormone test strip provided by the present invention is based on fluorescent microsphere immunochromatography technology. The thyroid stimulating hormone monoclonal antibody labeled with fluorescent microspheres is coated on the antibody pad. The surface curvature of the fluorescent microspheres is conducive to the exposed surface of the antigenic determinant and the antibody binding site being in a better reaction state. Since the fluorescent microspheres can carry many fluorescent molecules, only a small amount of low-energy radiation is required to generate a strong fluorescent signal, thereby reducing the cost while maintaining high sensitivity. 2) Compared with the chemiluminescence detection commonly used in clinical practice, the thyroid stimulating hormone detection test strip provided by the present invention does not require venous blood sampling. Only a small amount of peripheral blood is needed to obtain accurate test results within 15 to 20 minutes, which greatly improves the detection efficiency of thyroid stimulating hormone and enables patients to perform simple home monitoring. BRIEF DESCRIPTION OF THE DRAWINGS

[0087] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein: Figure 1 A schematic diagram of the structure of a thyroid stimulating hormone test strip provided in Example 1 of the present invention; Figure 2 This is a fitting curve diagram obtained by testing the test example of the present invention; Figure 3~Figure 5 They are respectively the fluorescence intensity curves of three peripheral blood samples tested in the test examples of the present invention; Figure 6 This is a linear relationship diagram of the test results of the present invention using TSH test strips and chemiluminescence method to detect peripheral blood and venous blood respectively.

[0088] Reference numerals: Blood filter pad 1; Antibody pad 2; Solid phase carrier 3, detection line 31, quality control line 32; Absorbent paper 4; Bottom plate 5. DETAILED DESCRIPTION

[0089] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0090] Materials and Definitions In the following examples, the sources of the main materials used are shown in Table 1.

[0091] Table 1 Information on main material sources

[0092] In the following examples, the main experimental instrument information used is shown in Table 2.

[0093] Table 2 Main test equipment information

[0094] Example 1 This embodiment provides a thyroid stimulating hormone test strip, and its structural schematic diagram is as follows Figure 1 As shown; the thyroid stimulating hormone test strip comprises: a blood filter pad 1, an antibody pad 2, a solid phase carrier 3, an absorbent paper 4 and a bottom plate 5; the blood filter pad 1, the antibody pad 2, the solid phase carrier 3 and the absorbent paper 4 are arranged on the bottom plate 5, the two ends of the antibody pad 2 are respectively connected to the blood filter pad 1 and the solid phase carrier 3, and the end of the solid phase carrier 3 away from the antibody pad 2 is connected to the absorbent paper 4; the solid phase carrier 3 is provided with a detection line 31 and a quality control line 32 spaced apart from each other, the detection line 31 is located at one end close to the antibody pad 2, and the quality control line 32 is located at one end close to the absorbent paper 4; the surface of the antibody pad 2 is coated with a first thyroid stimulating hormone antibody marked with fluorescent microspheres; the detection line 31 is fixed with a second thyroid stimulating hormone antibody; the quality control line 32 is fixed with a quality control antibody, and the quality control antibody can specifically bind to the first thyroid stimulating hormone antibody.

[0095] The preparation method of the thyroid stimulating hormone test strip specifically comprises the following steps: 1. Film cutting: 1) Use streaking solution to dilute the quality control antibody (sheep anti-mouse IgG) and the second TSH antibody (capture antibody). The specific formula of the streaking solution is shown in Table 3. The final concentration of the quality control antibody after dilution is 0.5 mg / mL, and the final concentration of the second TSH antibody after dilution is 2 mg / mL; 2) Confirm the position of the membrane stripper pump. Before stripping, clean the membrane stripper 5 times with 75% alcohol and 10 times with pure water. If the reverse suction method is used, it is necessary to suck a section of air column and then reversely suck the antibody. If the forward suction method is used, the pipeline must be filled with antibodies according to the usage of the Shanghai Jinbiao membrane stripper. After the filling is completed, a simulated run can be performed to confirm the membrane stripping position, and then the membrane stripping needle module can be pressed down to strip the membrane on the nitrocellulose membrane (solid phase carrier). The quality control antibody corresponds to the quality control line, and the second TSH antibody corresponds to the detection line. 3) After the membrane is drawn, dry it at room temperature and place it in a 37°C oven to dry for 12 h to obtain the drawn nitrocellulose membrane.

[0096] 2. Marking: 1) Preparation before marking: Adjust the centrifuge speed to 16,000 rpm and 22°C, take out EDC and NHS in advance and equilibrate to room temperature; place frozen ice packs in the ultrasonic cleaning machine to prevent the microspheres from overheating during the ultrasonic process; each step of ultrasonication should ensure the thorough dispersion of the microspheres.

[0097] 2) Washing of microsphere stock solution: Use 50 mM MES with pH 5.2 as coupling buffer, add 1 mL coupling buffer to a 2 mL centrifuge tube; add 50 μL fluorescent microspheres, vortex and sonicate for 2 min (to prevent aggregation of the microsphere stock solution), then add 0.5 mL coupling buffer and vortex again; place in a centrifuge and centrifuge at 16000 rpm for 10 min; aspirate the supernatant and discard (be careful not to aspirate the microspheres), add 500 μL coupling buffer three times, vortex and sonicate for 2 min each time; place in a centrifuge again and centrifuge at 16000 rpm for 10 min.

[0098] 3) Activation of microspheres: Use coupling buffer to dilute EDC and NHS to 5 mg / mL respectively. Prepare them before use and do not dilute them in advance. Add 14 μL of EDC diluent to the microsphere suspension after washing in step 2) and vortex until the solution is mixed, then add 132 μL of NHS diluent and vortex until the solution is mixed; After sealing with sealing film, place it on an oscillator at 700 rpm (Qilin Bell first gear) and shake for 30 min at room temperature (about 25°C) in the dark to obtain activated microspheres.

[0099] 4) Coupling of microspheres and antibodies: Take the activated microspheres in step 3) and centrifuge at 16,000 rpm for 10 min; aspirate the supernatant and discard it (be careful not to aspirate the microspheres), add 500 μL 10 mM MES buffer (pH 6.2) three times, vortex and sonicate for 2 min each time; place in a centrifuge and centrifuge at 16,000 rpm for 10 min; The supernatant was aspirated and discarded (be careful not to aspirate the microspheres), and 400 μL of 10 mM MES buffer (pH 6.2) was added twice, vortexing and sonicating for 2 min each time to obtain a microsphere solution; Add 50 μg of the first TSH antibody to 200 μL of 10 mM MES buffer (pH 6.2) and mix well, then add it to the above microsphere solution and vortex mix immediately; seal it with a sealing film, place it in a vortex mixer, and react for 2 h at 70 rpm and room temperature (about 25°C) in the dark.

[0100] 5) Closure of microspheres: After the reaction in step 4) is completed, add 500 μL of microsphere blocking solution to the reaction system. The specific formula of the microsphere blocking solution is shown in Table 3; after sealing with a sealing film, place it in a vortex mixer at 70 rpm and room temperature (about 25°C) in the dark for 1.5 hours.

[0101] 6) Microsphere storage: After the reaction in step 5) is completed, the reaction system is transferred to a centrifuge and centrifuged at 16000 rpm for 10 min; the supernatant is aspirated and discarded (be careful not to aspirate the microspheres), and 500 μL of microsphere washing solution is added three times. The specific formula of the microsphere washing solution is shown in Table 3. Each time, ultrasonication is performed for 2 min, vortexing, and centrifugation at 16000 rpm for 10 min; Aspirate the supernatant and discard it (be careful not to aspirate the microspheres), add 500 μL of microsphere washing solution three times, sonicate for 2 min, vortex, and centrifuge at 16000 rpm for 10 min each time; aspirate the supernatant and discard it (be careful not to aspirate the microspheres), add 500 μL of microsphere preservation solution, sonicate and vortex until there is no aggregation; place in a 4°C refrigerator to equilibrate overnight to obtain the first thyroid-stimulating hormone antibody labeled with fluorescent microspheres.

[0102] 3.Fixed: Use microsphere fixing solution to dilute the first thyrotropin antibody labeled with fluorescent microspheres obtained in step 2 by 20 times to a final concentration of 1.5 mg / mL; use a pipette to evenly spread the diluted fluorescent microspheres on the antibody pad, or use a film spraying instrument in gold spraying mode to spray the antibody pad; After drying at room temperature until there are no droplets on the surface, it is placed in a 37°C oven and dried for 2 h to obtain an antibody pad coated with the first thyroid stimulating hormone antibody labeled with fluorescent microspheres.

[0103] 4. Assembly and cutting: After sticking the streaked nitrocellulose membrane obtained in step 1, the absorbent paper, the antibody pad coated with the first thyroid stimulating hormone antibody labeled with fluorescent microspheres obtained in step 3, and the blood filter pad to the bottom plate, adjust the parameters of the strip cutting machine to 3.8 mm; cut the strips according to the required amount; after cutting the strips, use the card shell to install the test strips to obtain the thyroid stimulating hormone test strips.

[0104] Table 3 Formula of the solution used in Example 1

[0105] Test example This test example tests the detection of TSH content in different samples by the thyroid stimulating hormone test strip provided in Example 1. This test example also tests the chemiluminescence method commonly used in clinical practice as a control; the specific test method and test results are as follows: 1. Draw the fitting curve: The TSH standard purchased from the National Center for Standard Materials was used as the sample to be tested. 60 μL of the sample to be tested was added to 100 μL of sample diluent (10 mM PBS buffer containing 1 w / v% bovine serum albumin, 1 w / v% casein, 0.1 w / v% sucrose and 0.4 w / v% Tween-20, pH 7.0) and mixed thoroughly. Then 80 μL of the diluted sample was added dropwise to the sample compartment of the TSH test paper provided in Example 1. After waiting for the reaction for 15 min, the fluorescence detector was used for detection. The obtained results were plotted into a fitting curve, and the fitting curve is shown in FIG. Figure 2 shown.

[0106] Figure 2 The X-axis represents the measured value, and the Y-axis represents the concentration value; according to the four-parameter regression / fitting model "Y=(AD) / [1+(X / C)*B]+D", the following are calculated: parameter A: -0.22791, parameter B: 1.88718, parameter C: 0.49598, parameter D: 69.81464; fitting range: 0-1.0.

[0107] Take three peripheral blood samples of different concentrations and test them according to the above method. The fluorescence intensity curves of the quality control line and the test line are as follows: Figure 3~Figure 5 As shown; wherein, the left peak is the fluorescence intensity of the quality control line, and the right peak is the fluorescence intensity of the detection line. The specific fluorescence intensity readings and the concentrations calculated according to the fitting model are shown in Table 4.

[0108] Table 4 Peripheral blood fluorescence detection data

[0109] 2. Accuracy test: 1) In this test example, TSH standard substances of different concentrations (purchased from the National Center for Standard Materials) were used to test the detection accuracy of the thyroid stimulating hormone test strip provided in Example 1, that is, 80 μL of standard substances of known concentration were taken and dropped into the sample compartment of the TSH test strip provided in Example 1, and the reaction was waited for 15 min before detection using a fluorescence detector, and the concentration was calculated using the four-parameter formula obtained by the above fitting. The results are shown in Table 5.

[0110] Table 5 Accuracy test results based on standard substances

[0111] From the results in Table 5, it can be seen that the relative error of the TSH test strip provided by the present invention is less than 5% when detecting high, medium and low concentration standards, indicating that the detection accuracy of the test strip is high and suitable for widespread clinical use.

[0112] 2) In this test example, peripheral blood samples (whole blood) with different TSH concentrations were used to test the detection accuracy of the thyroid stimulating hormone test strip provided in Example 1, that is, 60 μL of peripheral blood samples were taken and added to 100 μL of sample diluent, mixed thoroughly, and then 80 μL of the diluted sample was added dropwise to the sample compartment of the TSH test strip provided in Example 1. After waiting for the reaction for 15 minutes, the fluorescence detector was used for detection, and the concentration was calculated by combining the four-parameter formula obtained by the above fitting; the peripheral blood samples were also tested for TSH concentration using the chemiluminescence method in parallel, and the results are shown in Table 6.

[0113] Table 6 Accuracy test results based on peripheral blood samples

[0114] From the results in Table 6, it can be seen that the relative error of the TSH test strip provided by the present invention is less than 5% when detecting peripheral blood samples of different concentrations, indicating that the detection accuracy of the test strip is high and suitable for wide clinical use.

[0115] 3. Linear relationship: In this test example, the TSH test strips provided in Example 1 and the chemiluminescence method were used to detect the matched peripheral blood and venous blood samples, respectively. The results are shown in Table 7.

[0116] Table 7 Peripheral blood fluorescence test data and chemiluminescence venous blood test results (μIU / mL)

[0117] Based on the data shown in Table 7, the results in Table 7 were plotted for linear analysis, and the results obtained are as follows Figure 6 shown.

[0118] From Table 7 and Figure 6 It can be seen from the data that the linear correlation coefficient of the TSH test strip provided by the present invention is 0.9881, which has a high linear correlation with the current gold standard chemiluminescence method, indicating that the detection results of the TSH test strip of the present invention are accurate and highly reliable.

[0119] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. A thyroid stimulating hormone test strip, characterized in that: The thyroid stimulating hormone test strip comprises: a blood filter pad (1), an antibody pad (2), a solid phase carrier (3), absorbent paper (4) and a bottom plate (5); The blood filter pad (1), the antibody pad (2), the solid phase carrier (3) and the absorbent paper (4) are arranged on the bottom plate (5). The two ends of the antibody pad (2) are respectively connected to the blood filter pad (1) and the solid phase carrier (3). One end of the solid phase carrier (3) away from the antibody pad (2) is connected to the absorbent paper (4); The solid phase carrier (3) is provided with a detection line (31) and a quality control line (32) spaced apart from each other, the detection line (31) is located at one end close to the antibody pad (2), and the quality control line (32) is located at one end close to the absorbent paper (4); The surface of the antibody pad (2) is coated with a first thyroid stimulating hormone antibody labeled with fluorescent microspheres; A second thyroid stimulating hormone antibody is fixed on the detection line (31); A quality control antibody is fixed on the quality control line (32), and the quality control antibody can specifically bind to the first thyroid stimulating hormone antibody.

2. The thyroid stimulating hormone test strip according to claim 1, characterized in that The mass ratio of the fluorescent microspheres to the first thyroid stimulating hormone antibody is (5-15):

1.

3. The thyroid stimulating hormone test strip according to claim 1, characterized in that The fluorescent microspheres include a high molecular polymer containing rare earth elements; And / or, the first thyroid stimulating hormone antibody comprises an anti-human thyroid stimulating hormone antibody.

4. The thyroid stimulating hormone test strip according to claim 1, characterized in that: The second thyroid stimulating hormone antibody comprises an anti-human thyroid stimulating hormone antibody; And / or, the quality control antibody comprises goat anti-mouse IgG.

5. A method for preparing a thyroid stimulating hormone test strip as claimed in any one of claims 1 to 4, characterized in that: The preparation method comprises the following steps: S1: Immobilizing a second thyroid stimulating hormone antibody on a solid phase carrier (3) to form a detection line (31), and immobilizing a quality control antibody on a solid phase carrier (3) to form a quality control line (32) spaced apart from the detection line (31); S2: coating the first thyroid stimulating hormone antibody labeled with fluorescent microspheres on the surface of the antibody pad (2); S3: The blood filter pad (1), the antibody pad (2) coated with the first thyroid stimulating hormone antibody labeled with fluorescent microspheres described in step S2, the solid phase carrier (3) fixed with the detection line (31) and the quality control line (32) described in step S1, and the absorbent paper (4) are arranged on the bottom plate (5) to obtain a thyroid stimulating hormone detection test strip.

6. The preparation method according to claim 5, characterized in that: The first thyroid stimulating hormone antibody labeled with fluorescent microspheres in step S2 is prepared by the following preparation method: A1: Mix the fluorescent microspheres, 1-ethyl-(3-dimethylaminopropyl)carbodiimide solution and N-hydroxysuccinimide solution to obtain activated fluorescent microspheres; A2: mixing the first thyroid stimulating hormone antibody with the activated fluorescent microspheres obtained in step A1 to obtain the first thyroid stimulating hormone antibody coupled to the fluorescent microspheres; A3: Add the microsphere blocking solution to the first thyroid stimulating hormone antibody coupled with the fluorescent microspheres obtained in step A2 and mix well to react, thereby obtaining the first thyroid stimulating hormone antibody labeled with the fluorescent microspheres.

7. The preparation method according to claim 6, characterized in that: The mass ratio of the fluorescent microspheres in step A1 to the first thyroid stimulating hormone antibody in step A2 is (15-5):

1.

8. The preparation method according to claim 5, characterized in that: The coating in step S2 includes: covering the first thyroid stimulating hormone antibody labeled with fluorescent microspheres on the surface of the antibody pad (2) and drying it, and then drying it at 30-40° C. for 1-3 hours.

9. Use of the thyroid stimulating hormone test strip as described in any one of claims 1 to 4 in the preparation of a product for rapid detection of thyroid stimulating hormone.

10. A kit, characterized in that: The kit comprises the thyroid stimulating hormone test strip as described in any one of claims 1 to 4.